Paper Details

  1. Home
  2. Paper Details

Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial.

Author: AccomandoWilliam, BettegowdaChetan, BotaDaniela, BremSteven, ButowskiNicholas, CachiaDavid, ChenClark C, CloughesyTimothy F, DamekDenise, ElderBrad, GruberHarry, HoganDaniel, IwamotoFabio, KabbinavarFairooz, KaptainGeorge, KheohThian, KimLyndon, LandolfiJoseph, MontellanoTiffany T, MoshelYaron, OstertagDerek, PerryJames, PetreccaKevin, PiccioniDavid, PlacantonakisDimitris, RaoAliz R, SalaczMichael, VogelbaumMichael A, WalbertTobias, ZhuJay-Jiguang

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Vocimagene amiretrorepvec (Toca 511) with flucytosine (Toca FC) did not improve overall survival or other efficacy end points compared to standard of care (SOC) in patients with recurrent high-grade glioma who underwent tumor resection.
Paper Details　
Original Abstract of the Article :
IMPORTANCE: New treatments are needed to improve the prognosis of patients with recurrent high-grade glioma. OBJECTIVE: To compare overall survival for patients receiving tumor resection followed by vocimagene amiretrorepvec (Toca 511) with flucytosine (Toca FC) vs standard of care (SOC). DESIGN, ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596685/

データ提供：米国国立医学図書館（NLM）

The Fight Against Glioma: A Camel's Journey Through Cancer Treatment

Glioma, a type of brain tumor, is a challenging condition to treat. This study investigates the effectiveness of a new treatment approach involving vocimagene amiretrorepvec (Toca 511) combined with flucytosine (Toca FC) in patients with recurrent high-grade glioma. The researchers conducted a randomized clinical trial comparing Toca 511/FC to standard of care (SOC) therapies in patients who had undergone tumor resection. The trial aimed to assess overall survival (OS) and safety of the new treatment approach.

A Camel's Search for Effective Therapies: Fighting Glioma with New Tools

This study explores the potential of a novel treatment approach for recurrent high-grade glioma, investigating the safety and effectiveness of Toca 511/FC compared to SOC therapies. The trial's findings provide valuable insights into the potential benefits and limitations of this new treatment option.

The Camel's Wisdom on Cancer Care: Harnessing Innovation

This study encourages the development and investigation of novel treatments for challenging cancers like glioma. It underscores the importance of clinical trials in evaluating the safety and effectiveness of new therapies, paving the way for advancements in cancer care.

Dr. Camel's Conclusion

Just as a camel overcomes the harsh desert environment, finding new treatments for challenging conditions like glioma requires persistence and innovation. This study highlights the ongoing search for effective therapies, offering hope for patients facing this difficult diagnosis.

Date :
  1. Date Completed 2021-02-11
  2. Date Revised 2021-10-30
Further Info :

Pubmed ID

33119048

DOI: Digital Object Identifier

PMC7596685

Related Literature

Article Analysis
・Effects of temozolomide injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.